Departments of Pediatric Hematology and Oncology.
Pediatrics.
J Pediatr Hematol Oncol. 2021 Mar 1;43(2):e165-e168. doi: 10.1097/MPH.0000000000001720.
Secondary expansion and/or evolution of aggressive subclones are associated with the disease progression and resistance to chemotherapy in neuroblastoma, and it is important to track the clonal changes during the treatment period. Cell-free (cf) DNA analysis, namely liquid biopsy, can detect the genomic change of tumor cells without surgical procedures. In this report, we showed that serial polymerase chain reaction-based cf DNA neuroblastoma proto-oncogene quantification is sensitive enough to evaluate the aggressive cellular characteristics of ALK/MYCN-coamplified neuroblastoma and stressed the promise of cf DNA analyses as a reliable molecular marker in advanced neuroblastoma.
次级扩增和/或侵袭性亚克隆的进化与神经母细胞瘤的疾病进展和化疗耐药有关，因此在治疗期间跟踪克隆变化非常重要。无细胞（cf）DNA 分析，即液体活检，可以在无需手术的情况下检测肿瘤细胞的基因组变化。在本报告中，我们表明，基于聚合酶链反应的连续 cfDNA 神经母细胞瘤原癌基因定量分析足够灵敏，可以评估 ALK/MYCN 共扩增神经母细胞瘤的侵袭性细胞特征，并强调了 cfDNA 分析作为晚期神经母细胞瘤可靠分子标志物的潜力。
